Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

KBIO $26.83 8.4299 +45.81%
OHRP $4.60 0.6251 +15.75%
CTIX $1.81 0.2400 +15.29%
AEZS $8.64 0.9599 +12.50%
SNTA $0.48 0.0447 +10.18%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NWBO $4.76 -0.2100 -4.23%
VBLT $5.66 -0.2200 -3.74%
THLD $3.79 -0.0800 -2.07%
PVCT $0.44 -0.0088 -1.98%
SRNE $8.42 -0.1600 -1.86%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Executive View - FDA Approval Is Single Biggest Genmab Moment - CEO

(Reuters) Nov 17, 2015 - Danish biotech firm Genmab GEN.CO said late on Monday the U.S. Food and Drug Administration had approved its cancer treatment Darzalex (daratumumab) for blood cancer multiple myeloma.
read article 

Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101

(Yahoo! Finance) Nov 17, 2015 - Three-party collaboration will explore synergies between AstraZeneca’s leading PARP inhibitor and Cerulean’s topoisomerase inhibitor.
read article 

Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data

(TheStreet) Nov 17, 2015 - Quality of life was maintained throughout treatment with Tumor Treating Fields; EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who received chemotherapy alone.
read article 

Amgen to Present IMLYGIC (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research

(Amgen) Nov 16, 2015 - Highlights include analyses from pivotal study and new data from phase 1b combination trial in metastatic melanoma.
read corporate press release 

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses

(Merck) Nov 17, 2015 - Merck, known as MSD outside the United States and Canada, today announced that data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year.
read corporate press release 

Nondrug Interventions Improve Quality Of Life For Chinese Cancer Patients

(University Of Illinois At Urbana-Champaign) Nov 17, 2015 - A meta-analysis of dozens of studies of traditional Chinese medicine and other nonpharmacological interventions meant to improve patients' quality of life affirms that these approaches, on the whole, help alleviate depression, fatigue, pain, anxiety, insomnia and gastrointestinal problems in Chinese cancer patients.
read press release 

Deeper Grasp of Chemotherapy-Induced Peripheral Neuropathy

(Medscape Medical News) Nov 12, 2015 - Two unrelated studies, both published in the Journal of Clinical Oncology, provide deeper insights into peripheral neuropathy — a disabling side effect experienced by patients on many chemotherapy regimens, particularly regimens containing oxaliplatin (Eloxatin, sanofi-aventis) and paclitaxel (multiple brands).
read article (free registration required) 

Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy

(Georgia Tech) Nov 17, 2015 - Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
read article 

Pre-Op Blood Tests May Predict Post-Op Morbidity in Ovarian CA

(Physician’s Briefing/HealthDay News) Nov 16, 2015 - Pre-op thrombocytosis, leukocytosis tied to post-op morbidity; increased mortality for patients with both.
read article 

Nanotech-based Sensor Developed To Measure MicroRNAS In Blood, Speed Cancer Detection

(Indiana University-Purdue University Indianapolis) Nov 17, 2015 - A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
read press release 

UK Researchers Develop Pancreatic Cancer Treatment ‘Breakthrough’

(PharmaTimes [UK]) Nov 17, 2015 - Ulster University has developed a pioneering treatment for pancreatic cancer, which researchers are hailing as the first breakthrough in over 40 years that could significantly boost survival rates.
read article 

Kidney Failure And Its Treatment May Impact Cancer Risk

(Medical News Today) Nov 13, 2015 - For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer.
read article 

Roche Breast Cancer Drug At Center Of UK Pricing Row

(Reuters) Nov 16, 2015 - A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the centre of a drug pricing row after Britain's health cost agency declared that it is still too expensive.
read article 

FDA Speedy Review For BMS' Opdivo In Kidney Cancer

(PharmaTimes [UK]) Nov 17, 2015 - US regulators are undertaking a priority review of Bristol-Myers Squibb’s immunotherapy Opdivo for the treatment of patients with advanced renal cell carcinoma, the most common form of kidney cancer which kills more than 100,000 people every year.
read article 

U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma

(StreetInsider) Nov 16, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and priority review a supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
read article 

NICE: Kadcyla Price Still Too High

(NICE) Nov 17, 2015 - Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), will not be recommended for routine NHS use because its price remains too high.
read press release 

FDA Approves Adynovate for Hemophilia A

(Medscape Medical News) Nov 13, 2015 - The US Food and Drug Administration (FDA) has approved Adynovate, a new recombinant PEGylated antihemophilic factor for children aged 12 years or older and adults with hemophilia A.
read article (free registration required) 

Study Shows Merck Hepatitis C Drug Cures Addicts

(Bloomberg) Nov 14, 2015 - Hepatitis C patients who use intravenous drugs were cured at a high rate by Merck & Co.’s experimental therapy, a study found, a result that could put pressure on U.S. states to more broadly cover new treatments for a group that’s at high risk of reinfection.
read article 

US Drug Benefit Managers Clamp Down On Specialty Pharmacies

(Reuters) Nov 16, 2015 - In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters.
read article 

FDA Approves Darzalex For Patients With Previously Treated Multiple Myeloma

( Nov 16, 2015 - Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
read press release 

ESUI15 – Ultrasound in Urology: Emerging Trends

(EAU) Nov 12, 2015 - Emerging trends in the use of ultrasound in urological cancers were discussed at the 4th EAU Section of Urological Imaging (ESUI15) with novel techniques such as “super-fast” and micro-ultrasound which provide detailed images to physicians.
read press release 

KaloBios to Wind Down Operations

(StreetInsider) Nov 13, 2015 - KaloBios Pharmaceuticals, Inc. today announced that it will wind down its operations and that it has engaged the Brenner Group to lead those efforts.
read article 

AstraZeneca's Potential $3 Billion Cancer Pill Wins Early Approval

(Reuters) Nov 13, 2015 - A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, won early U.S. approval on Friday, in a boost for the British drugmaker.
read article 

Former Health Secretary Andrew Lansley Takes On Roche Advisory Role

(Pharmafile [UK]) Nov 16, 2015 - Former UK health secretary Andrew Lansley has taken on work as an advisor to Roche in the midst of ongoing controversy over drug pricing and the future of the Cancer Drugs Fund (CDF).
read article 

New York Businessman Grants Millions To MD Anderson

(Houston Business Journal) Nov 16, 2015 - Andrew Sabin, a New York-based businessman and philanthropist, committed $30 million to support cancer research at the University of Texas MD Anderson Cancer Center.
read article